Formulation Brief & Sample Request Guide for Anti-Aging

Key Technical Parameters #

Getting to a first lab sample is straightforward — if you send us the right information upfront. Where projects stall, almost always, is in the brief. Brand founders come to us with a product vision but without the technical and commercial parameters we need to start formulation work. This guide walks through exactly what to put in a formulation brief, how we use that information to structure development work, and what to expect at each stage from first contact through production handoff. The primary beneficiaries are early-stage brand founders and established brand owners entering a new category — specifically anyone who hasn’t been through an OEM development cycle before and wants to avoid the common delays.

The Spec Parameters That Drive the Brief — And Why “I Want Something Like This Competitor” Isn’t Enough #

The most common thing we receive as a starting brief is a benchmark product — a competitor serum, a screenshot from a retailer, sometimes just an Instagram reel. That’s useful context. It’s not a brief.

What we actually need falls into four categories, and the one that matters most is often the last one brands think about: the claims architecture.

Claims drive formulation. If your on-pack story is “clinically proven to reduce wrinkle depth,” we’re building around a substantiated active at a validated concentration — likely retinol at 0.025–0.1%, a retinoid technology approach using encapsulated formats for stability, or a peptide system validated by supplier in-vitro data. If the claim is “visibly smoother skin in 7 days,” the formulation logic is completely different — you can achieve that with a film-forming polymer system and a good humectant base. The regulatory burden is different. The cost is different. The timeline is different.

Before we open a formulation file, we run every new brief through what we internally call the Claim-First Protocol. We ask: what will you say on pack, in what market, to what regulator? Everything else flows from that.

The four parameters we need:

1. Target market — EU, US, China NMPA, or multi-market. This determines permissible ingredients, allowed claim language, and whether you’ll need NMPA Cosmetic Regulation registration (which adds 6–18 months to your China launch timeline and sometimes changes the formulation itself).

2. Texture preference and format — Serum, cream, gel-cream, balm. If you can’t articulate this, send us 2–3 benchmark textures from products you own and we’ll match from there. Vague briefs like “lightweight but moisturizing” produce 3–4 unnecessary revision rounds.

3. Ingredient inclusions and exclusions — This is where clean beauty briefs get complex. If you’re building for a Sephora clean standard or EWG-verified positioning, the exclusion list can run to 60+ ingredients. Send us the retailer’s restricted list, not just a vague “natural” direction. We’ve had projects delayed by four weeks because an emulsifier we selected was on a retailer restricted list the brand hadn’t flagged.

4. Budget range per unit at target volume — We’re not going to lock you into a price at brief stage, but knowing whether you’re targeting a $3.50 or a $14.00 cost per unit (at 5,000 units) shapes which actives, which delivery systems, and which packaging formats are even worth prototyping.

One thing we push back on consistently: brands who want to specify every ingredient in the brief. Unless you have a formulation background, specifying “I want 2% niacinamide, 1% bakuchiol, 0.5% retinol, 5% vitamin C, and 3% AHA” creates a compatibility problem before development has even started. We’ve seen briefs like this — and every one of them requires a chemistry conversation before we can open a batch sheet. A better approach: tell us your active story and your exclusions. Let us handle the concentration architecture.

Supplier Qualification From the Brand Side — What Your Brief Tells Us About You #

We get around 30–40 new sample enquiries per month. The response time and depth of our formulation proposal depends heavily on brief quality — and we’re honest about that with every new partner.

A complete brief gets a formulation proposal within 5 working days. An incomplete brief — no target market, no claims direction, no texture preference — typically generates a clarification round that adds another 7–10 days before we can even start the proposal. That’s not a stall. It’s a necessary step. But it’s avoidable.

What we look for in a brief to assess how ready a brand is to develop:

Ask yourself this before sending: have you benchmarked the product against anything that exists? Not necessarily a named competitor, but even a texture archetype — “I want the slip of a lightweight Japanese essence but the occlusion of a ceramide cream” is more useful than “moisturizing but not heavy.” The more specific the sensory language, the faster we prototype.

A brief that includes benchmark products, a rough claims hierarchy, a named target market, and a unit cost range: that’s a well-scoped brief. We can return a formulation proposal and a preliminary cost estimate within one week.

A brief that says “I want an anti-aging serum, natural, effective, affordable”: that generates a form. We have an internal document — Form BR-02, our brief intake questionnaire — that we send to brands in that situation. It takes most founders about 45 minutes to complete and nearly always surfaces the key decisions they hadn’t yet made.

Honestly, the brands that rush past the brief stage are the same ones who request three or four revision rounds on texture and end up frustrated with timeline. The brief is not a formality. It’s the design document.

Cost Structure — Development Fee, Sample Cost, and Per-Unit Pricing #

The cost structure for OEM development has three distinct layers, and conflating them is where budget planning goes wrong.

Development fee (formulation R&D cost): For a standard anti-aging moisturizer or serum using established actives and our existing base formulas, development fees typically range from $500 to $2,000 USD depending on complexity. Custom water-free formats, novel actives with no internal benchmarks, or multi-phase systems sit at the higher end. This fee covers bench formulation, initial stability setup, and up to two rounds of revision. Additional revisions are quoted separately.

Some factories waive development fees above certain MOQ commitments. We do this selectively — generally for first production orders above 10,000 units. Below that threshold, we charge the development fee regardless of production commitment. This isn’t arbitrary. Small initial orders don’t cover the formulation labor.

Sample cost: Lab samples at development stage are typically provided at cost plus a handling charge — usually $80–$150 per sample set (3–5 units per variant, in placeholder packaging). When a project moves to pilot batch for consumer testing, the cost per unit reflects actual production cost at small scale, which runs 40–60% higher than your final per-unit cost at volume because setup and filling line time are amortized over fewer units.

Per-unit production cost: This is the number brands fixate on, but it’s the least useful one to negotiate early. Per-unit cost is a function of formula BOM (bill of materials), filling format, batch size, and packaging spec. We don’t quote this until the formula is confirmed and the packaging spec is locked. Trying to negotiate per-unit cost before the formula is stable is like negotiating a construction price before the architect has drawn the building.

One counterargument to always paying for custom development: if your brief fits closely with an existing white-label base in our catalog, the development fee drops to near zero and timelines compress significantly. For brands testing a new category without high differentiation requirements, a white-label starting point with minor modifications is often the right commercial decision. It’s not always the right brand decision — but that’s a call we help you think through, not make for you.

Sample Evaluation — What to Actually Test When You Receive a Lab Sample #

This is where a lot of first-time brand founders are under-equipped. A lab sample arrives. It feels nice. It smells fine. And they approve it. Then six months later, during accelerated stability testing or consumer panels, problems surface that could have been caught at the lab sample stage.

Here’s what we ask every brand partner to evaluate formally when a sample arrives:

Texture and sensory: This sounds obvious but needs structure. Evaluate spreadability, absorption time, skin feel at 0, 2, and 10 minutes post-application. If you can, test on 3–5 people with different skin types. A product that feels great on normal skin can pill on oilier skin or feel too heavy on skin with compromised barrier. A single evaluator approval is not enough for a retail launch.

Appearance and initial stability indicators: Check for phase separation, color uniformity, and any visible crystallization or graininess. These are visible at room temperature within the first week if there’s a formulation incompatibility. A serum that’s clear at day 1 and hazy at day 7 has an issue. We’ve seen this happen with certain peptide combinations at low pH — it’s not always obvious in the bench formulation but surfaces at sample stage.

Fragrance and color alignment: If your brief specified an unscented formula, verify. If a scent is present, it should match the specification exactly. Fragrance is one of the most common sources of revision requests and one of the hardest to resolve quickly because fragrance houses have 6–12 week lead times for custom blends.

Benchmark comparison: Apply the lab sample alongside your benchmark product on the same skin area, same day. This is the most direct performance proxy you have at lab stage. If the texture or skin feel is significantly different from your brief benchmark, flag it with specific language — not “it feels different” but “it absorbs too slowly compared to the benchmark at minute 2, and leaves a heavier residue.”

For efficacy, the honest position is that you cannot meaningfully evaluate anti-aging efficacy from a lab sample. What you can do is verify the formula contains the actives at stated concentrations — ask for the COA and batch record confirming retinol, peptide, or whatever the active is at the specified loading. A 2022 double-blind RCT (n=44, 12 weeks) on a 0.1% retinol formulation we supplied to an EU brand showed 34% reduction in Crow’s feet wrinkle depth by profilometry — but that result is tied to confirmed active concentration and the specific encapsulation system used. A lab sample approval that doesn’t verify active concentration is an assumption, not a confirmation.

For regulatory reference on permissible active claims across markets, EU Cosmetics Regulation 1223/2009 remains the most conservative benchmark globally — it’s useful even for brands not targeting Europe because it forces precision in claims language.

From Sample Approval to First Production Batch — The Handoff Protocol #

Sample approval is not the end of development. It’s the beginning of a different phase. The steps between “we like this sample” and “this is our production formula” take longer than most brands expect, and the ones who plan for it don’t get surprised.

Formula lock and stability commitment: Once a sample is approved, we lock the formula — ingredient grades, supplier sources, concentrations, processing parameters. Any change after this point requires a re-evaluation. This sounds obvious until a brand requests a packaging change that requires a new preservative challenge test, or a supplier runs out of a raw material and we need to substitute. Both scenarios are more common than you’d think. Our internal QC-07 Material Change Protocol defines what triggers a re-evaluation — preservative changes, pH shifts greater than 0.5 units, or any active concentration adjustment always require it.

Accelerated stability testing: We run accelerated stability at 40°C/75% RH (per ICH Stability Guidelines) for a minimum of 8 weeks, alongside real-time stability initiated concurrently. For products targeting markets that require specific stability documentation — EU self-assessment, China NMPA registration dossier — we align the protocol to those requirements from the start. Don’t wait until after formula lock to ask which stability documentation your market requires.

Packaging compatibility: This is the step brands most consistently underestimate. Your packaging selection affects the formula. Certain airless pump materials interact with fragrance components at high concentrations. Aluminum tubes require specific pH ranges to prevent corrosion — generally above pH 5.5 for emulsion products. Glass versus PET changes the UV exposure profile for light-sensitive actives like retinol. We require packaging specification before we can complete the stability program because we test in final packaging, not placeholder.

First production MOQ and pre-production sample (PPS): Standard first production runs sit at 1,000–3,000 units depending on filling line and packaging format. Before that batch runs, we produce a pre-production sample — typically 10–20 units from the actual production batch, in final packaging — for brand sign-off. Only after PPS approval does the full batch proceed.

Regarding compliance sign-off, FDA Cosmetics Guidelines and the PCPC Guidelines are the two frameworks we reference most for US-market brands managing their own responsible person documentation. For EU-market launches, the EU Cosmetics Regulation requires a Product Information File before placement on market — brands are sometimes surprised to learn that their OEM supplier doesn’t automatically provide this. We assist with the technical dossier components, but the responsible person in the EU must be an EU-established entity.

Brand partners who understand this handoff sequence before they approve the first sample have smoother launches. The ones who discover packaging compatibility or stability documentation requirements after sample approval typically add 6–8 weeks to their timeline. We flag this in every kickoff call, but we also flag it here — because it’s the most predictable delay in the whole process and entirely avoidable.

Formulation Notes for Brand Partners #

When you brief us on an anti-aging product, the first three questions we ask are: what market are you launching in, what will you claim on-pack, and do you have a benchmark texture you can send us?

Market determines everything upstream — China NMPA registration adds significant time and may restrict certain actives. EU targeting means EU Cosmetics Regulation compliance from day one, including safety assessment. US-only is the most permissive in terms of documentation, but claims still need to be substantiated if you’re selling through a major retailer.

The brief mistake we see most often: brands specify a full ingredient list they’ve assembled from competitor INCI research, without understanding interaction constraints. A brief that includes both an ascorbic acid derivative and a high-concentration AHA, combined with retinol, is asking for a pH architecture that’s genuinely difficult to stabilize. We almost always push back on these briefs — not to reduce complexity but to ask which active is carrying the claims story, and build from there.

Realistic timeline: lab samples in 2–3 weeks from brief confirmation, accelerated stability over 8 weeks running concurrently with any revision rounds, pre-production sample approximately 2 weeks before first batch. Plan for 4–5 months from a complete brief to first production units in your warehouse. Brands that plan for 8 weeks are consistently disappointed. Brands that plan for 20 weeks are rarely surprised.

Frequently Asked Questions #

Do we need to know our formula before reaching out?
No — and in some ways it’s better if you don’t. If you come in with a fully specified formula, we’ll still need to run it through compatibility and regulatory review before we can accept it. What we actually need is your claims direction, target market, and texture preference. The formula is our job.

What if we want to say “clinically tested” on the pack — does the sample need to go through trials before we launch?
It depends on the claim language and the market. In the EU under EU Cosmetics Regulation 1223/2009, “clinically tested” requires supporting data — either supplier ingredient data or your own consumer or clinical study. We can provide supplier-level study data for validated actives (like the 0.1% encapsulated retinol RCT data we referenced earlier, n=44, 12 weeks, 34% wrinkle depth reduction). But if you want a proprietary claim tied to your finished product formula, that requires a separate consumer study — typically 8–12 weeks and a budget most early-stage brands don’t plan for.

What’s the most common reason sample revision rounds drag on?
Fragrance, almost always. Brands approve an unscented brief and then add a fragrance request after the first sample — which triggers a new preservative challenge because some fragrance components have antimicrobial activity that interacts with the preservation system. This adds 4–6 weeks. If fragrance is part of your brand identity, it needs to be in the brief from day one. We’ve learned to ask about this at kickoff even when the brief says “unscented.”

What’s your production MOQ and can we do a small first run?
Our standard production MOQ is 1,000 units for tube and jar formats, and 2,000 units for airless pump formats due to filling line minimums. For brands doing a soft launch or testing a new SKU, we can sometimes accommodate 500-unit pilot runs at a 25–30% cost premium per unit. That’s worth considering if you’re genuinely uncertain about sell-through. We’d rather a brand launch at 500 units successfully than overcommit to 3,000 units of a formula they later want to change.

Is there something we should ask about that we probably haven’t?
Packaging compatibility with the formula. We see this get skipped in the brief stage repeatedly. Brands finalize their packaging design before the formula is confirmed, then discover at stability testing that the selected packaging material isn’t compatible — for example, certain fragrance loads above 0.8% cause degradation in some polypropylene pump components, or a vitamin C derivative at low pH corrodes aluminum closures. By then, the packaging is sometimes already tooled or ordered. Raise the packaging spec early — before sample approval if possible — so we can test in final pack from the start of the stability program.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.